AU
UK
CA
US
IND
NZ
Last update at 2026-06-12T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
Wed 15 Jan 25, 12:34 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -2.57800M | -5.78900M | -3.53500M | -4.47900M | -9.00900M |
| Minority interest | 0.00000M | 0.00000M | 0.05M | -0.10800M | 0.43M |
| Net income | -2.59200M | -5.80100M | -3.50700M | -5.36200M | -8.52300M |
| Selling general administrative | 5.38M | 3.64M | 1.72M | 2.40M | 5.81M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 1.02M | 1.07M | 0.55M | 0.50M | 0.84M |
| Reconciled depreciation | 0.19M | 0.03M | 0.16M | 0.18M | 0.15M |
| Ebit | -7.38000M | -5.76800M | -3.29300M | -4.10800M | -8.76400M |
| Ebitda | -8.50600M | -5.74100M | -2.59200M | -3.73400M | -8.61700M |
| Depreciation and amortization | -1.12600M | 0.03M | 0.70M | 0.37M | 0.15M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -7.38000M | -5.76800M | -3.29300M | -4.10800M | -9.71400M |
| Other operating expenses | 8.73M | 5.77M | 2.55M | 4.11M | 9.29M |
| Interest expense | 0.04M | 0.01M | 0.03M | 0.57M | 0.12M |
| Tax provision | 0.01M | - | - | - | -0.06000M |
| Interest income | - | 0.00000M | 0.63M | 0.30M | 0.50M |
| Net interest income | -1.24000M | -0.01800M | -0.23000M | -0.37300M | 0.40M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.01M | 0.01M | -0.02800M | 0.88M | -0.06000M |
| Total revenue | 1.35M | 1.07M | 0.55M | 0.50M | 0.84M |
| Total operating expenses | 8.40M | 5.77M | 2.55M | 4.11M | 9.29M |
| Cost of revenue | 0.32M | - | - | - | - |
| Total other income expense net | 4.80M | -0.02100M | -0.24200M | -0.37100M | -0.12200M |
| Discontinued operations | - | - | - | -0.20700M | -2.41500M |
| Net income from continuing ops | -2.59200M | -5.78900M | -3.53500M | -4.47900M | -8.94900M |
| Net income applicable to common shares | -2.59200M | -5.78900M | -3.48200M | -4.79400M | -8.52300M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 11.18M | 10.61M | 9.92M | 2.56M | 1.15M |
| Intangible assets | 3.19M | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.28M | 0.10M | 0.39M | 0.32M | 0.02M |
| Total liab | 1.59M | 4.16M | 1.77M | 1.13M | 1.14M |
| Total stockholder equity | 7.61M | 6.45M | 8.14M | 1.43M | 0.01M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 0.72M | 2.93M | 1.27M | 0.67M | 0.00700M |
| Common stock | 64.53M | 58.59M | 58.54M | 49.04M | 6.32M |
| Capital stock | 64.53M | 58.59M | 58.54M | 49.04M | 6.32M |
| Retained earnings | -68.69100M | -63.56900M | -60.97700M | -55.18800M | -51.70600M |
| Other liab | - | - | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | - | 0.02M |
| Cash | 2.14M | 3.57M | 6.88M | 1.95M | 0.87M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 1.57M | 4.16M | 1.76M | 1.13M | 1.05M |
| Current deferred revenue | - | - | -0.15400M | - | 0.29M |
| Net debt | -2.06500M | -3.54700M | -6.37100M | -1.48100M | -0.37000M |
| Short term debt | 0.05M | 0.03M | 0.49M | 0.47M | 0.41M |
| Short long term debt | - | - | 0.44M | 0.47M | 0.41M |
| Short long term debt total | 0.08M | 0.03M | 0.50M | 0.47M | 0.50M |
| Other stockholder equity | 0.00000M | 10.93M | 10.08M | 7.08M | 44.90M |
| Property plant equipment | - | 0.06M | 0.09M | 0.01M | 0.17M |
| Total current assets | 6.45M | 4.51M | 9.82M | 2.55M | 0.95M |
| Long term investments | 1.44M | 1.32M | - | - | - |
| Net tangible assets | - | 1.73M | 8.14M | 1.43M | 0.01M |
| Short term investments | 3.00M | - | - | - | - |
| Net receivables | 0.29M | 0.17M | 2.56M | 0.29M | 0.06M |
| Long term debt | - | - | - | - | - |
| Inventory | 0.74M | 0.67M | - | - | - |
| Accounts payable | 0.80M | 1.20M | 0.15M | 0.28M | 0.34M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 11.78M | 0.50M | 0.50M | 0.50M | 0.50M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | - | - | - | 0.02M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 4.74M | 6.09M | 0.09M | 0.01M | 0.20M |
| Capital lease obligations | 0.08M | 0.03M | 0.06M | 0.00000M | 0.09M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -7.08400M | -0.07000M | 0.02M | 1.27M | -2.09400M |
| Change to liabilities | 0.00000M | 0.35M | -0.75200M | -0.84000M | 0.18M |
| Total cashflows from investing activities | -7.08400M | -0.07000M | 0.02M | 1.27M | -2.09400M |
| Net borrowings | -0.07000M | -0.20700M | 0.22M | -0.04700M | 1.57M |
| Total cash from financing activities | 11.70M | 10.06M | 5.36M | 2.80M | 1.54M |
| Change to operating activities | 0.04M | 0.12M | -0.07500M | -1.61000M | 1.32M |
| Net income | -2.59200M | -5.78900M | -3.53500M | -4.68600M | -8.94900M |
| Change in cash | -3.30100M | 4.93M | 1.08M | -0.61500M | -7.71000M |
| Begin period cash flow | 6.88M | 1.95M | 0.87M | 1.49M | 9.20M |
| End period cash flow | 3.57M | 6.88M | 1.95M | 0.87M | 1.49M |
| Total cash from operating activities | -7.91700M | -5.06100M | -4.30700M | -4.69600M | -7.13200M |
| Issuance of capital stock | 9.01M | 7.70M | 2.65M | 2.22M | 0.00000M |
| Depreciation | 0.19M | 0.03M | 0.16M | 0.18M | 0.15M |
| Other cashflows from investing activities | -0.01500M | -0.03500M | 0.02M | -0.00100M | -0.01000M |
| Dividends paid | 0.00000M | 0.00000M | 0.00000M | 0.00000M | - |
| Change to inventory | -0.66800M | -0.66800M | 0.52M | -0.66800M | 0.65M |
| Change to account receivables | -0.07700M | 0.17M | -0.51900M | 0.33M | -0.09900M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | 2.77M | 2.57M | 4.14M | 0.64M | 1.54M |
| Change to netincome | -4.80900M | 0.05M | 0.36M | 2.04M | -0.15100M |
| Capital expenditures | 4.87M | 0.04M | 0.04M | 0.00100M | 0.02M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -0.70300M | 0.64M | -1.34600M | -2.12100M | 1.40M |
| Stock based compensation | 0.90M | 0.04M | 0.09M | 0.55M | 0.60M |
| Other non cash items | -5.70600M | 0.00900M | -0.47600M | 0.16M | -0.26900M |
| Free cash flow | -12.78600M | -5.09600M | -4.30700M | -4.69700M | -7.14900M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SPRC Scisparc Ltd |
-0.76 8.16% | 8.55 | - | - | 1.43 | 0.54 | 0.05 | 0.17 |
| NVO Novo Nordisk A/S |
-0.08 0.18% | 43.88 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
1.99 4.74% | 44.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-0.115 0.03% | 444.93 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
0.66 0.11% | 612.14 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Tower A, Tel Aviv, Israel, 6971916
| Name | Title | Year Born |
|---|---|---|
| Mr. Oz Adler C.P.A. | CEO & CFO | 1986 |
| Mr. Itschak Shrem | Pres & Director | 1947 |
| Dr. Adi Zuloff-Shani Ph.D. | Chief Technologies Officer | 1970 |
| Mr. Oz Adler CPA | CEO & CFO | 1987 |
| Mr. Itschak Shrem | President & Director | 1947 |
| Dr. Adi Zuloff-Shani Ph.D. | Chief Technologies Officer | 1969 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...